Table 4 Pharmacokinetic parameters

From: A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours

 

1.25 mg kg −1

5 mg kg −1

10 mg kg −1

20 mg kg −1

30 mg kg −1

No. of patients

3

2

3

3

7

T max (hours)

 Mean (arithmetic)

4.03

1.07a

2.12

1.12

2.8

 Median

1.08

1.37

1.12

1.17

 CV%

128

77.1

11.1

119

 Max

10

4

1.25

9.88

 Min

1

1

1

1

Cmax g ml−1)

 Mean (arithmetic)

31.6

88.5

231

593

758

 Median

27.8

88.5

235

616

752

 CV%

21.1

4.28

15.4

9.82

16

 Max

39.2

91.1

265

637

974

 Min

27.6

85.8

194

527

630

AUC (day*μg ml−1)

 Mean (arithmetic)

319

882

1980

5020

6610

 Median

327

882

1930

4960

6680

 CV%

40

3.83

16.7

9.9

20.7

 Max

442

906

2340

4960

8830

 Min

188

858

1680

4550

4660

Vss (ml kg−1)

 Mean (arithmetic)

53.5

100

71.2

47.3

59.2

 Median

56.5

100

66.6

45.8

54.7

 CV%

26.9

21

18.3

9.95

18.4

 Max

66.1

115

85.9

52.6

71

 Min

37.8

85.4

61

43.5

50.5

CL (ml day−1 kg−1)

 Mean (arithmetic)

4.44

5.68

5.14

4.01

4.72

 Median

3.83

5.68

5.18

4.03

4.49

 CV%

44.8

3.83

16.3

9.77

21.5

 Max

6.66

5.83

5.95

4.39

6.44

 Min

2.83

5.52

4.28

3.61

3.4

t 1/2 (days)

 Mean (arithmetic)

9.36

13.4

10.6

8.99

9.88

 Median

9.41

13.4

10.5

8.52

9.08

 CV%

32.7

28

19.1

9.54

28.8

 Mean (geometric)

9.01

13.1

10.5

8.96

9.55

 Mean (harmonic)

8.67

12.8

10.4

8.94

9.25

 Max

12.4

16

12.7

9.98

14.7

 Min

6.28

10.7

8.69

8.47

6.89

Cmin (μg ml−1)

 Mean (arithmetic)

45b

72b

189b

84c

102c

 Median

35

83

164

81

108

 CV%

81.6

30.9

30.3

7.97

26.1

 Max

85.7

87.2

268

92

139

 Min

14.5

46.7

135

79.6

69.1

  1. Abbreviations: Tmax=time of maximum concentration after intravenous infusion; Cmax=maximum observed concentration after intravenous infusion; CV%=coefficient of variation; AUC=area under curve (the area under the concentration–time curve, from time zero to infinity); Vss=volume of distribution at steady state; CL=plasma clearance; t1/2=terminal half life
  2. aOne patient.
  3. bTrough concentration is calculated as the mean of individual concentrations before dose 8 (n=3).
  4. cTrough concentration is calculated as the mean of individual concentrations before dose 3 (n=3 for 20 mg kg−1 and n=8 for 30 mg kg−1).